 |
MaxCyteSince 1999, MaxCyte's non-viral cell engineering innovations have helped launch pioneering cell and gene therapy projects. |
|
|
|
| As advanced therapeutic modalities move from concept to clinic, new cell engineering approaches will emerge and mature. MaxCyte will continue to leverage their best-in-class electroporation technology and experience in the industry to support our partners in pushing the frontiers of bio-based medicines. |
Electroporation Systems |
||||||||
|
||||||||
 |
 |
 |
 |
||||
ATx™ |
STx™ |
GTx™ |
VLx™ |
||||
| For small to medium scale R&D transfection |
For complex proteins, vaccines and biologics | For cGMP manufacturing of cell-based therapies |
For gram scale protein production |
||||
| Advance your research with an electroporator designed for reproducible, high-efficiency transfection of 75 thousand to 700 million cells | Decrease development timelines and costs with efficient, reproducible transient transfection that can delay the need for stable cell line development | Safely and efficiently transfect up to 20 billion cells with the only clinically validated electroporator developed with cell therapy in mind | Accelerate recombinant protein development with the ability to transition seamlessly from discovery to manufacturing | ||||
| Brochure | Brochure | Brochure | Brochure | ||||
Consumables |
|
 |
 |
||||||
Processing
|
Reagents & Supporting Products |
||||||
| ExPERT PAs ‘Processing Assemblies’ for R&D and cGMP development |
Reagents and accessories for quick and easy electroporation discovery |
||||||
| Advance your project goals and milestones while maintaining the high levels of efficiency, viability, and consistency your therapy deserves. | Develop protocols and handle precious samples confidently with one line of compatible reagents and accessories. | ||||||
| more | more |